Ultima Genomics
Latest round
- Series A
Last raised
- Dec 2017
Total raised
- $31M
Investors
- 3
About Ultima Genomics
Ultima Genomics, Inc. focuses on developing innovative DNA sequencing solutions aimed at enhancing genomic research accessibility and efficiency. Founded in 2016 and headquartered in California, US, Ultima Genomics, Inc. specializes in DNA sequencing technology. The founder, Gilad Almogy, is also the CEO, bringing a wealth of experience in the genomics sector.00 mn, serving as a strong financial backing for their growth initiatives. Ultima Genomics specializes in high-throughput and cost-effective DNA sequencing solutions, primarily through its flagship product, the UG 100 Sequencing Platform. This innovative platform utilizes advanced sequencing architecture designed to enhance throughput and reduce costs, addressing key challenges in the genomics industry, such as scalability and accessibility of sequencing technologies. The UG 100 allows for the generation of up to 12 billion reads per wafer, enabling the analysis of over 30,000 genomes annually. The company's offerings also include the Solaris library prep workflows and bioinformatics analysis tools, which are optimized for seamless integration with third-party library preparation providers. Ultima Genomics serves a diverse clientele, including research institutions, clinical laboratories, and biopharmaceutical companies across various geographical markets, including North America, Europe, and Asia. Ultima Genomics generates revenue primarily through the sale of its UG 100 Sequencing Platform and associated services, including sequencing runs and library preparation workflows. The company's business transactions occur predominantly on a B2B basis, with clients engaging in partnerships and collaborative projects to leverage Ultima's sequencing technology for various genomic research applications. Pricing structures are based on service agreements and may involve transaction models that include pay-per-sequencing run or subscription packages for ongoing access to sequencing services and support. The UG 100 platform and Solaris workflows are key revenue drivers, as clients utilize these tools for applications in whole genome sequencing, oncology research, and proteomics, enabling them to achieve advancements in genomic science and personalized medicine.
Who invested in Ultima Genomics
3 investors across 2 rounds
See all investors in Ultima Genomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ultima Genomics
Who invested in Ultima Genomics?
Ultima Genomics has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ultima Genomics raised?
Ultima Genomics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ultima Genomics last raise money?
Ultima Genomics's most recent round on record is a Series A, in Dec 2017.
What does Ultima Genomics do?
Ultima Genomics is a biotechnology company.
Where is Ultima Genomics headquartered?
Ultima Genomics is headquartered in Fremont, US.
Which VCs invest in companies like Ultima Genomics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ultima Genomics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ultima Genomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.